Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI

OncoImmunology

Volumn 2, Issue 11, 2013, Pages

  Vincent, Marie ^a   Quéméner, Agnès ^a   Jacques, Yannick ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Cancer therapy; GD2 disialoganglioside; Immunocytokine; Interleukin 15; RLI superagonist

Indexed keywords

CYTOKINE; GANGLIOSIDE GD2 ANTIBODY INTERLEUKIN 15 RECEPTOR ALPHA FUSION PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 15 RECEPTOR ALPHA FUSION PROTEIN; INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG PROTEIN BINDING; HUMAN; IMMUNOSTIMULATION; KIDNEY CARCINOMA; LYMPHOMA; MELANOMA; NEUROBLASTOMA; NONHUMAN; PROTEIN EXPRESSION;

EID: 84892414620     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26441     Document Type: Article

References (10)

1. Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn MA, Ahdieh M, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994; 264:965-8; PMID:8178155; http://dx.doi.org/10.1126/science.8178155.
2. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008; 222:357-68; PMID:18364014; http://dx.doi. org/10.1111/j.1600-065X.2008.00604.x.
3. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2012; 33:35-41; PMID:22032984; http://dx.doi.org/10.1016/j. tips.2011.09.004.
4. Mortier E, Bernard J, Plet A, Jacques Y. Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol 2004; 173:1681-8; PMID:15265897.
5. Mortier E, Quéméner A, Vusio P, Lorenzen I, Boublik Y, Grötzinger J, Plet A, Jacques Y. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem 2006; 281:1612-9; PMID:16284400; http://dx.doi.org/10.1074/jbc. M508624200.
6. Bessard A, Solé V, Bouchaud G, Quéméner A, Jacques Y. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009; 8:2736-45; PMID:19723883; http://dx.doi.org/10.1158/1535-7163.MCT-09-0275.
7. Pasche N, Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 2012; 17:583-90; PMID:22289353; http://dx.doi. org/10.1016/j.drudis.2012.01.007.
8. Vincent M, Bessard A, Cochonneau D, Teppaz G, Solé V, Maillasson M, Birklé S, Garrigue-Antar L, Quéméner A, Jacques Y. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency. Int J Cancer J Int Cancer 2013.
9. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737.
10. Birklé S, Zeng G, Gao L, Yu RK, Aubry J. Role of tumor-associated gangliosides in cancer progression. Biochimie 2003; 85:455-63; PMID:12770784; http://dx.doi.org/10.1016/S0300-9084(03)00006-3.